Loading clinical trials...

Azithromycin in Bronchiolitis Obliterans Syndrome | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Azithromycin in Bronchiolitis Obliterans Syndrome

Randomized Double-blind Placebo-controlled Prevention Trial of Azithromycin in Lung Transplantation.

NCT01009619•KU Leuven

Summary

Preventive treatment with azithromycin reduces the prevalence fo Bronchiolitis Obliterans Syndrome after lung transplantation.

Detailed Description

* Prospective, interventional, randomized, double-blind, placebo-controlled trial. * Clinical setting (tertiary University Hospital). * Investigator-driven, no pharmaceutical sponsor. * Lung transplant recipients. * Add-on of study-drug (placebo or azithromycin) to 'standard of care' (standardized, routine immunosuppressive and infectious prophylactic protocol). * 1:1 inclusion ratio (placebo:azithromycin). * Randomisation at discharge after informed consent.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Stable LTx recipients at discharge after transplantation.
•Signed informed consent
•Adult (age at least 18 years old at moment of transplantation)
•Able to take oral medication

Exclusion Criteria

•Prolonged and/or complicated ICU-course after transplantation.
•Early (\<30 days post-transplant) post-operative death
•Major suture problems (airway stenosis or stent)
•Retransplantation (lung)
•Previous transplantation (solid organ)
•Multi-organ transplantation (lung+ other solid organ)

Locations (1)

Katholieke Universiteit Leuven and University Hospital Gasthuisberg

Leuven, Belgium

Key Dates

Start Date

September 1, 2005

Primary Completion Date

December 1, 2009

Completion Date

December 1, 2009

Last Updated

October 3, 2011

Enrollment

ACTUAL participants

Conditions

Bronchiolitis Obliterans SyndromeGraft RejectionLymphocytic BronchiolitisRespiratory Infection

Interventions

Azithromycin

DRUG

Placebo

DRUG

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

NCT00106925

Graft-versus-leukemiaGraft vs Host Disease+1 more

View study

RECRUITING

Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

NCT06532890

Cardiac FailureGraft Rejection

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 3, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Azithromycin in Bronchiolitis Obliterans Syndrome

Inclusion Criteria

Exclusion Criteria

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Response to Extracorporeal Photo-aphereSiS

VIRTUUS Children's Study

Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts